Is AEON Stock Undervalued?

A comprehensive valuation analysis of Aeon Biopharma Inc (AEON) examining current multiples, intrinsic value, and comparing to analyst expectations.

Updated January 21, 2026•8 min read•View Full Analysis

Valuation Verdict

↑

Potentially Undervalued

56963843502.2% upside potential

Based on our analysis, Aeon Biopharma Inc appears to be potentially undervalued at the current price of $1.12. Our fair value estimate of $637995048.34 suggests upside potential of approximately 56963843502.2%.

Current Valuation Metrics

Valuation ratios help us understand how the market is pricing AEON relative to its fundamentals. Let's examine the key multiples investors are paying today.

P/E Ratio

N/A

P/B Ratio

N/A

P/S Ratio

97.16

High

EV/EBITDA

N/A

Understanding the Metrics

P/E Ratio: Not currently profitable or data unavailable.
P/B Ratio: Book value data not available.
P/S Ratio: The price-to-sales ratio of 97.16 indicates how much investors value each dollar of revenue.
EV/EBITDA: EBITDA data not available.

Fair Value Estimate

Using a discounted cash flow (DCF) model, we estimate the intrinsic value of Aeon Biopharma Inc stock. This fundamental analysis looks at the company's ability to generate future cash flows and discounts them back to today's value.

Current Price

$1.12

Fair Value Estimate

$637995048.34

Implied Return+56963843502.2%

Our DCF model suggests AEON may be undervalued by approximately 56963843502.2%. This implies the market may be pricing in more pessimistic growth expectations than our base case scenario.

Analyst Price Targets

Wall Street analysts provide price targets based on their fundamental research and models. Let's see how the consensus view compares to the current price.

Current Price

$1.12

→

Analyst Target

$7.20

Implied Upside542.9%

The consensus analyst price target of $7.20 suggests 542.9% upside potential from current levels. Analysts appear optimistic about the stock's prospects.

Investment Conclusion

Bottom Line

Based on our comprehensive valuation analysis, Aeon Biopharma Inc (AEON) appears to be undervalued at $1.12. With a fair value estimate of $637995048.34, the stock offers potential upside for long-term investors willing to wait for the market to recognize its intrinsic value.

Disclaimer: This analysis is for informational purposes only and should not be considered investment advice. Always conduct your own research and consult with a financial advisor before making investment decisions. Past performance does not guarantee future results.